Effect of simvastatin/ezetimibe 10/ versus simvastatin on serum vitamin D levels.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

Low levels of 25-hydroxyvitamin D (25(OH)VitD) have been recognized as an emerging cardiovascular disease (CVD) risk factor.

Who Took Part

The study group was 40 patients.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized and open-label study.

The patients were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Everyone knew when Vitamin D, K2, Magnesium and Zinc was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

The primary end point was between-group difference in the change of serum 25(OH)VitD levels.

What Was Measured

Low levels of 25-hydroxyvitamin D (25(OH)VitD) have been recognized as an emerging cardiovascular disease (CVD) risk factor.

The subject headings attached to it are 25-Hydroxyvitamin D 2, Anticholesteremic Agents, Azetidines, Calcifediol, Cardiovascular Diseases, Drug Combinations and Ezetimibe, Simvastatin Drug Combination.

What This Means in Plain Language

The paper is a randomized and open-label study of Vitamin D, K2, Magnesium and Zinc in 40 patients.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2013 (Journal of cardiovascular pharmacology and therapeutics), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.